PixarBio establishes research center to advance spinal cord injury, epilepsy, non-addictive pain platform

PixarBio Corporation announced it has established the JP Reynolds Research Center in Woburn, Mass. to advance research in spinal cord injuries, epilepsy and non-addictive pain toward market.

According to a press release, the center will focus on research and development (R&D) products, such as epilepsy drug delivery systems, the morphine replacement NeuroRelease, and neuroscaffolds and injectable neuroscaffolds for acute and chronic spinal cord injuries (SCIs).

“Neuroscience is the unknown frontier in medicine, but our skillsets and patents are leading us to take on the most challenging neurological diseases in new ways, with success in our labs it is time to drive spinal cord and epilepsy product toward market,” Frank Reynolds, PixarBio chief executive officer, said in the press release. “My brother’s life-long seizures shortened his life by 20 years, and new treatment options never seem to materialize, so we jumped in and have promising data for epilepsy that we look forward to advancing through our labs. You can never have too many spinal cord injury inventions so we will use the JP Reynolds Research Center to continue to lead the SCI R&D space.”

The first product FDA approval for the NeuroRelease platform will be a 14-day postoperative pain treatment, which according to the release, is expected in early 2019.

Reference: